Lithium Cannabis Withdrawal Study

Study Overview
=================
Brief Summary
-----------------
This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.

Detailed Description
-----------------
There are currently no accepted pharmacotherapies for the management of cannabis withdrawal. A recent study by Cui et al (2001) investigated the effects and mechanism of lithium on cannabinoid withdrawal in rats. The researchers found that lithium administration prevented the development of withdrawal symptoms, and suggested that increased oxytocin secretion resulting from lithium dosing prevented the withdrawal syndrome from occurring. Although caution should be exercised in generalising the results of an animal study, preliminary results of a small pilot study in humans are consistent with the potential utility of lithium in the management of human cannabis withdrawal (Zhang, personal communication). Furthermore, human use of lithium is well established and the addition of a readily available drug such as lithium carbonate would be a useful clinical tool should it prove efficacious in a series of clinical trials.

Official Title
-----------------
An Open Label Trial of Lithium for the Management of Cannabis Withdrawal

Conditions
-----------------
Cannabis Dependence, Substance Withdrawal Syndrome

Intervention / Treatment
-----------------
* Drug: Lithium carbonate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV diagnosis of cannabis dependence with at least a three-month history. Seeking treatment for primary cannabis problem Withdrawal identified as barrier to abstinence Exclusion Criteria: Other drug dependency (excluding nicotine) Client is breastfeeding or pregnant. Client has contraindicated medical or psychiatric conditions. Client currently taking other medications that may interact with lithium. Known hypersensitivity / side effects with Lithium. Currently receiving Lithium from another source. Currently prescribed any antidepressant / mood stabilising / antipsychotic medication. Currently receiving opioid pharmacotherapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lithium carbonate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of reported cannabis withdrawal symptoms |  |  | 
| Treatment retention |  |  | 
| Cannabis use |  |  | 
| Depression |  |  | 
| Anxiety |  |  | 
| Aggression/Anger |  |  | 
| Sleep difficulty |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cannabis withdrawal, lithium, Cannabis withdrawal syndrome